Eris Lifesciences Balance Sheet Health
Financial Health criteria checks 5/6
Eris Lifesciences has a total shareholder equity of ₹24.3B and total debt of ₹8.3B, which brings its debt-to-equity ratio to 34.2%. Its total assets and total liabilities are ₹38.8B and ₹14.5B respectively. Eris Lifesciences's EBIT is ₹4.8B making its interest coverage ratio 8.3. It has cash and short-term investments of ₹1.9B.
Key information
34.2%
Debt to equity ratio
₹8.30b
Debt
| Interest coverage ratio | 8.3x |
| Cash | ₹1.91b |
| Equity | ₹24.28b |
| Total liabilities | ₹14.48b |
| Total assets | ₹38.75b |
Recent financial health updates
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20Recent updates
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Investor Optimism Abounds Eris Lifesciences Limited (NSE:ERIS) But Growth Is Lacking
Aug 22Eris Lifesciences Limited (NSE:ERIS) Looks Interesting, And It's About To Pay A Dividend
Aug 08Should You Buy Eris Lifesciences Limited (NSE:ERIS) For Its Upcoming Dividend?
Aug 08Eris Lifesciences Limited's (NSE:ERIS) Risks Elevated At These Prices
Jul 28Financial Position Analysis
Short Term Liabilities: ERIS's short term assets (₹9.6B) exceed its short term liabilities (₹5.0B).
Long Term Liabilities: ERIS's short term assets (₹9.6B) exceed its long term liabilities (₹9.5B).
Debt to Equity History and Analysis
Debt Level: ERIS's net debt to equity ratio (26.3%) is considered satisfactory.
Reducing Debt: ERIS's debt to equity ratio has increased from 26.5% to 34.2% over the past 5 years.
Debt Coverage: ERIS's debt is well covered by operating cash flow (53.6%).
Interest Coverage: ERIS's interest payments on its debt are well covered by EBIT (8.3x coverage).